b cell lymphoma prognosis | NHL statistics, B cell lymphoma survival rate.

NHL statistics, B cell lymphoma survival rate.

NHL statistics, B cell lymphoma survival rate.

The purpose of statistics is to find the median (similar to the average) the results and trends of the. Large groups. These calculations on the groups should not be confused with the prognosis of an individual.

The prognosis is based on individualized clinical factors, such as your age, the type of lymphoma, where it is in the body, the underlying biology, and the response to the initial treatment.

The statistics are calculated from the results that have taken place in the past, and will not account for the positive effects of new therapies and improvement management techniques on survival and quality of life.

Survival statistics on groups can be calculated in different ways. such as the percentage of all patients who are still alive at 5 years of age. Some patients interpret this means they cannot hope to live for five years. However, every year a patient survives lymphoma and the expected survival increases by 5 years. This is called the conditional on 5 years survival rate.

As in a marathon, those who have completed a few miles do better, on average, than all the riders who have entered the event. Most of the statistics are based on all riders in the race. For the most indolent lymphoma, the state of no-event survival at 12 months provides for a lifetime as long as that of the general population. For the most common aggressive lymphoma, being free from disease at 2 years predicts healing.

In the news:
Lymphoma Statistics – rate, count and annual percentage change – per sub-type prepared by PAL SEER Database 2014 PDF
Surprising/alarming rise mediastinal large B cell lymphoma

Haematologica 2013: Actual prognosis in the follow-up of B cells not Hodgkin lymphoma survivors in the Netherlands. 
Five-year relative survival was calculated for each additional year of survival up to 16 years after diagnosis, by entity, grade, sex, age, and Ann Arbor stage. The prognosis of indolent non-Hodgkin B cells with slightly improved lymphoma with each additional year survived up to 91%. For patients with non-Hodgkin's lymphoma aggressive conditional relative survival improved strongly during the first year after diagnosis (from 48% to 68%) and then gradually to 93% after 16 years.

Table 2: Conditional survival for patients with B-cell non-Hodgkin's lymphoma in the Netherlands 1989-2008 (n = 54015)

PAL: Base-SEER Lymphoma subtype Statistics SEER-NHL-subtype2. pdf
Statistics by Prognosis Report
The statistics should not be confused with predictions or prognosis. The purpose of the statistics is to find the average results and trends in large groups. The prognosis is based in part on statistics, but also on your unique situation, such as your age, fitness, and response to treatment.

Statistics can not predict what will happen to you or a loved one.

The term "5-year survival" refers to the proportion of people in research studies who were still alive 5 years after the diagnosis. However, patients who live 6, 10, or even 30 years after diagnosis are also in this group.

Importantly, mortality events include the death of any cause. Therefore, survival calculations for the group may be skewed if the average age of the affected population is greater than the mature age.

For example, what is the means of survival for all those at 65 years of age?

In addition, each year a patient survives lymphoma and the expected survival increases by 5 years. This is called the conditional on 5 years survival rate.

As in a marathon, those who have completed a few miles do better, on average, than all the riders who have entered the event. Most of the statistics are based on all riders in the race.

In addition, statistics take time to compile and can not show the influence of new therapies that many years later – I think the latency is about 5 years.

As indicated, overall survival for groups is calculated on the basis of death of any cause, and is strongly influenced by the average age at the time of diagnosis. For example, for follicular lymphomas a median bone of 8 to 10 years is often quoted and the average age at the time of diagnosis is about 65 years. However, a recent report from Stanford, based on patients with a median age of 49 years, the operating system was reported to be 18 years old.

See also the prognostic indicators and Jay Gould
Encouraging the test: The median is not the message
Median age at time of lymphoma diagnosis:
Prevalence of lymphoma:
 "This includes anyone living on January 1, 2007 who was diagnosed with Hodgkin's lymphoma at any time before January 1, 2007 and includes people with active disease and those who are cured of their disease."

Non-Hodgkins:  "On January 1, 2007, in the United States there were about 438325 men and women living with a history of non-Hodgkin's lymphoma – 226.855 men and 211.470 women. Seeing

Hodgkins:  "On January 1, 2007, in the United States there were about 164273 men and women living who had a history of Hodgkin lymphoma – 84.583 men and 79690 women.  "LED

Change in the prevalence of malignant lymphoid malignancies indolent among older persons ASCO 2006
Background: reported changes in incidence rates and improved survival rates in patients with common B-cell indolent lymphoid malignancies have potential implications for the increased burden of disease in Older people.

Conclusions: increased FL incidence and increased survival rates have resulted in a growing burden of morbidity among elderly people over the past decade; The prevalence of CLL/SLL remained static.

Follicular lymphoma: The median of survival for different molecular subtypes
 "Individual genes that predicted survival time were grouped into gene expression signatures based on their expression throughout the formation, and two of these signatures were used to construct a survival predictor. Both signatures allowed patients with samples in the test set to be divided into four quartiles with very disparate median lengths of survival (13.6, 11.1, 10.8 and 3.9 years), regardless of clinical prognostic variables. Flow Cytometry has shown that these signatures reflect gene expression by immune cells infiltrating non-malignant tumors.  ". org NEJM

Good news: Improved survival of follicular lymphoma patients in surveillance, epidemiology and final results (SEER) program. ASCO 2004

Abstract No: 6578

Costs not represented in statistics
Physical and emotional pain, side effects of repeated treatment, decreased ability to be productive, loss of income and life goals, stress on family and loved ones, and reduced ability to fully contribute to Our communities.

 "Not all that matters, can be counted; 
Not everything that can be counted  "

Lymphoma statistics in the United States
Incidence – New cases in a given year (can be expressed as a rate – often for 100,000.)
Source: SEER CSR Report 1975-2002

NOTE: For blood cancers, the risk is generally higher in white males. A notable exception to the risk of multiple myeloma in black men and women.


By comparing age-adjusted incidence rates:

Leukemias: 12.3 For 100,000 men and women per year risk * Lifetime: Lymphoma: 22.0 for 100,000 men and women per year. **

"It is estimated that 44240 men and women (24,800 men and 19,440 women) will be diagnosed with and 21,790 men and women will die of leukemia in 2007 "

"It is estimated that 71.380 men and women (38.670 men and 32.710 women) will be diagnosed with and 19.730 men and women will die of lymphoma in 2007 "

NOTE: CLL is classified by SEER as leukemia, but many experts consider it lymphoma.

Pennsylvania
County-based statistics – 
New York State
The incidence of non-Hodgkin's lymphoma increased by 76% for men and 49% for women between 1975 and 1994.

The non-Hodgkin's lymphoma mortality rate has steadily increased for men (19%) and women (17%) over the same period. "– Roswell Park Cancer Inst.

Staten Island
The study also found statistically significant elevations of 10 to 55% of the incidence of the following cancers on Staten Island as a whole: pharynx, colon, lung, bladder, larynx in men; and pharynx, colon, lung, breast, bladder, lymphoma in women. "

State of New York Cancer Registry Staten Island (Richmond) – 

For more information. See – Incidence of lymphoma in Staten Island & New York City

Cancer statistics
Resources to locate Cancer statistics
The magnitude of the human and economic costs of cancer in the United States is enormous. At the current rate, invasive cancer will be diagnosed in about 1 every 2 American men and 1 in 3 women in their lives. Cancer afflicts 2 on all 3 families. Annual cancer costs are estimated at approximately billion37 $1 billion 107 for direct medical expenses, $11 billion for loss of productivity, and 59 billion for indirect death costs. "

SEER statistics in brief – NHL | Hodgkin's (highly recommended)
SEER CSR report – 

 | Specific NHL | Specific-Hodgkin's
Changes in the incidence of non-Hodgkin lymphomas in the United States.
Cancer. 1 April 2002; 94 (7): 2015-23. PMID: 11932904 – PubMed | Related Abstracts
Every five minutes, someone in the United States learns that they have leukemia, lymphoma, or myeloma, more than 300 people a day. "– They
General state of Science
Extract from the report of leukemia, lymphoma and myeloma Progress Review Group May 2001 full text

"Despite advances in the diagnosis and treatment and improvement of patient survival, hematological cancers continue to have a significant impact on the lives of Americans."

At present, nearly 700,000 Americans live with leukemia, lymphoma, or myeloma (LLM), and about 100,000 new cases occur each year.

Although mortality has decreased and survival rates at 5 years have increased in adults and children suffering from certain forms of these diseases, it is estimated that 60,000 Americans will die of them in 2001.

For all forms of leukemia, the five-year survival rate is only 46%, for non-Hodgkin's lymphoma, it is 54.2%, and for multiple myeloma, it is only 28%.

Despite the significant drop in the mortality rate of children with leukemia, this disease causes even more deaths in children in the United States than any other disease.

In addition, mortality rates for non-Hodgkin lymphoma and multiple myeloma are increasing at a time when mortality rates for other cancers are declining.

Since the years 1970, incidence rates for non-Hodgkin's lymphoma have increased dramatically, making it one of the fastest growing cancers in the United States.

Hematologic cancers afflict individuals of all ages, from children to the elderly; Men and women; and all races.  "– LLMPRG Report

Lymphoma

Incidence & Mortality

Incidence & mortality lymphoma

Comment & QUESTIONS:

By including both indolent and aggressive NHL we are really the combination of two distinct conditions, especially when survival is considered, since aggressive is curable in maybe 40% of cases. It occurred to me yesterday to note that the reports SEER that almost 29% are still alive after 20 years. but which ones. Hopefully not only the 40% cured with aggressive, although mathematically, they must understand a large percentage. As time passes, we should try to distinguish more clearly the considerable differences between indolent and aggressive. In fact, it is a pity that our trouble is a not something. Especially since it exceeds largely Hodgkin's. It removes something from the public profile of the NHL. People want to support a  "not something "? – Robert Miller.

Q: I was diagnosed with stage 4 lymphoma-do you have any statistics on the survival rate of patients with this diagnosis?

A: There is a saying in the statistics that  "The median is * not * the message." Still also true for lymphomas (focus on plural) in which there are so many subtypes of the disease and people diagnosed with it. The factors that predict the average * * survival for PTS with lymphoma include the specific diagnosis, the stage of the disease (almost everyone is diagnosed with stage 4), the level of the patient's age and performance, the tumor load, the rate of High LDH, response to initial treatment and duration of initial reaction.

In addition, survival data is still a few seasons behind and does not take into account the impact of the more targeted new therapeutic approaches that are currently available, and of course the new treatments to arrive soon.

Resources:

View/download maps for non-Hodgkin's lymphoma – NCI | Text summary

Trends

A disturbing trend is that the incidence and mortality rates for the NHL have increased, the incidence rate has almost doubled since the early 1970 years, and then stabilisation over the past 5 years. For both forms of lymphoma, incidence and mortality are higher for whites than African-Americans and other ethnic groups. It is estimated that, every year, $2.6 billion * has been spent in the United States on the treatment of lymphoma.  "1

SEER adjusted by age incidence rate comparison
Adjusted and observed delay rates
For non-Hodgkin's lymphoma, all races, both sexes, all ages
SEER 9 Registries for 1975 at 2004
Age-adjusted to the United States STD Population 2000: FastStats
Childhood lymphomas
Disclaimer: The information on Lymphomation. is not intended to substitute for a professional medical opinion or to replace your relationship with a physician.
For all medical problems, you should always consult your doctor.
Patients against lymphoma, Copyright 2004, All rights reserved.